
About Bafna Pharma
Bafna Pharma is a publicly listed company based in Chennai (India) founded in 1981. Provider of formulation services for pharmaceutical industry. The company has 325 employees. Its Indian entity Bafna Pharmaceuticals Limited reported revenue of βΉ155 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Similar companies include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed similar companies have raised funding.
Company details
Bafna Pharma was established in 1981 in Chennai, India, within the pharmaceutical sector. Manufacturing services focused on formulations are offered, with emphasis on exports to regulated and rest-of-world markets. Domestic operations were initiated in 2011 through the acquisition and launch of Raricap, targeting gynaec and paediatric segments. The company operates from its base in India to serve global and local needs.
- Headquarters Chennai, India
- Employees 325
- Stage Public
- SectorsHealthcare
- Website bafnapharma.com
- Social LinkedIn X
- Legal Name Bafna Pharmaceuticals Limited
- Market Cap₹1,134 Cr
BAFNAPH · NSE
- Share Price₹469.95
-1.99% today
- Revenue₹42.47 Cr
FY 2019-20 · -2.7% YoY
- EBITDA−₹21.33 Cr
Margin -50.2%
- Net Profit−₹2.17 Cr
FY 2019-20 · +89.1% YoY
- Debt / Equity0.70
Interest cover -0.4x
- Employee Count325
Associated legal entities of Bafna Pharma
Bafna Pharma operates through Bafna Pharmaceuticals Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Bafna Pharmaceuticals Limited Listed CIN L24294TN1995PLC030698 | Active | 28 Mar 1995 | Chennai, Tamil Nadu | ₹155 Cr | 381 | 9 | View details |
Board of directors of Bafna Pharmaceuticals Limited (Bafna Pharma)
Bafna Pharmaceuticals Limited is the primary company behind Bafna Pharma. The board of Bafna Pharmaceuticals Limited currently have 6 directors; the longest-serving is Shanmugam Hemalatha, appointed in 2020. 23 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Shanmugam Hemalatha DIN 02714329 | Whole-time director | 10 Sep 2020 | 6 yrs 2 mo | Bafna Pharmaceuticals Limited |
| Akila Chintalapati Raju DIN 07590312 | Director | 10 Sep 2020 | 6 yrs 2 mo | Bafna Pharmaceuticals Limited |
| Ravichandran Chitra DIN 07749125 | Director | 12 Nov 2020 | 6 yrs | Bafna Pharmaceuticals Limited |
| Vinayak Dinesh Dendukuri DIN 07601309 | Whole-time director | 26 Jun 2023 | 3 yrs 4 mo | Bafna Pharmaceuticals Limited |
| Upendar Mekala Reddy DIN 08898174 | Director | 26 Jun 2023 | 3 yrs 4 mo | Bafna Pharmaceuticals Limited |
| Palamadai Krishnan Sundaresan DIN 06954189 | Director | 19 Sep 2025 | 1 yr 2 mo | Bafna Pharmaceuticals Limited |
IPO & Listings of Bafna Pharma
Bafna Pharma is a publicly listed company on the NSE with ticker symbol BAFNAPH in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Feb 2020
- Listed onNSE: BAFNAPH
- Listed entityBafna Pharmaceuticals Limited
- Exchange sectorHealth technology
- ISININE878I01022
- Share price₹443.50 (+1.99% on the day) · 2026-10-14
- Market capitalisation₹1,046 Cr
- Price to earnings134.7
- EPS (diluted, trailing year)₹3.29
- Volume (last session)2,305
Financials of Bafna Pharma
Exchange-reported figures of Bafna Pharmaceuticals Limited, the listed company behind Bafna Pharma (NSE: BAFNAPH).
Financial Highlights
FY 2019-20 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 42.47 | 43.63 | 47.17 | 64.96 | 85.32 | 97.67 | 185 |
| Revenue growth | -2.7% | -7.5% | -27.4% | -23.9% | -12.6% | -47.3% | - |
| EBITDA | (21.33) | (13.07) | (35.12) | (5.82) | 0.51 | (20.51) | 22.83 |
| EBITDA margin | -50.2% | -30.0% | -74.5% | -9.0% | +0.6% | -21.0% | +12.3% |
| Profit before tax | (24.44) | (17.28) | (14.70) | (20.37) | (15.33) | 6.05 | 2.48 |
| Net profit | (2.17) | (19.88) | (44.56) | (19.10) | (14.04) | (29.86) | 1.39 |
| Net profit margin | -5.1% | -45.6% | -94.5% | -29.4% | -16.5% | -30.6% | +0.8% |
| EPS (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.31 | 0.75 |
| Balance sheet | |||||||
| Total assets | 54.21 | 65.71 | 96.70 | 137 | 139 | 142 | 179 |
| Net worth | 51.12 | 19.06 | 37.93 | 42.67 | 57.76 | 71.78 | 68.86 |
| Total debt | 3.02 | 46.23 | 46.54 | 82.38 | 80.48 | 68.65 | 108 |
| Cash & bank | 8.48 | 2.71 | 2.95 | 2.66 | 2.71 | 2.77 | 2.81 |
| Net working capital | 18.99 | 0.88 | 12.17 | 39.09 | 72.73 | 73.02 | 106 |
| Cash flow | |||||||
| Cash from operations | (34.31) | (1.79) | (7.05) | (0.95) | 0.91 | 10.66 | 1.61 |
| Cash from investing | 32.77 | 15.36 | 37.97 | (5.42) | (0.36) | 60.13 | (6.71) |
| Cash from financing | 7.30 | (13.81) | (30.63) | 6.31 | (0.61) | (70.83) | (13.16) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 151 | 146 | 152 | 115 | 85.14 | 71.22 | 42.47 |
| Revenue growth | +3.3% | -4.3% | +32.2% | +35.5% | +19.6% | +67.7% | - |
| EBITDA | 15.94 | 9.03 | 11.11 | 15.70 | 9.80 | 10.30 | (22.10) |
| EBITDA margin | +10.6% | +6.2% | +7.3% | +13.6% | +11.5% | +14.5% | -52.0% |
| Profit before tax | 10.97 | 4.15 | 7.34 | 11.60 | 5.22 | 5.83 | (25.21) |
| Net profit | 11.10 | 6.37 | 7.27 | 11.12 | 7.38 | 5.83 | (1.88) |
| Net profit margin | +7.4% | +4.4% | +4.8% | +9.6% | +8.7% | +8.2% | -4.4% |
| EPS (βΉ) | 4.69 | 1.76 | 3.11 | 4.79 | 2.21 | 2.46 | (106.54) |
| Balance sheet | |||||||
| Total assets | 138 | 115 | 107 | 97.60 | 73.87 | 72.16 | 53.96 |
| Net worth | 96.15 | 84.81 | 80.84 | 73.46 | 61.97 | 56.77 | 50.95 |
| Total debt | 37.43 | 28.20 | 24.39 | 22.93 | 11.06 | 15.29 | 3.02 |
| Cash & bank | 2.02 | 3.43 | 1.40 | 7.81 | 0.17 | 1.80 | 8.48 |
| Net working capital | 52.12 | 47.05 | 53.33 | 55.32 | 34.61 | 35.35 | 18.77 |
| Cash flow | |||||||
| Cash from operations | 15.37 | 22.14 | 9.48 | 4.95 | 9.73 | (13.61) | (34.27) |
| Cash from investing | (22.40) | (21.16) | (15.05) | (7.49) | (6.54) | (5.35) | 32.78 |
| Cash from financing | 5.62 | 1.06 | (0.85) | 10.18 | (4.81) | 12.28 | 7.27 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 47.67 | 26.58 | 42.24 | 38.29 | 35.47 | 34.62 | 39.06 | 33.19 |
| Revenue growth (YoY) | +34.4% | -23.2% | +8.1% | +15.4% | -12.0% | +4.0% | - | - |
| Other income | 1.13 | 1.91 | 1.76 | 1.22 | 1.18 | 0.60 | 1.03 | 0.19 |
| Total expenses | 39.06 | 25.70 | 38.69 | 35.24 | 31.19 | 29.56 | 37.74 | 30.14 |
| EBITDA | 8.61 | 0.88 | 3.55 | 3.05 | 4.28 | 5.06 | 1.32 | 3.05 |
| EBITDA margin | +18.1% | +3.3% | +8.4% | +8.0% | +12.1% | +14.6% | +3.4% | +9.2% |
| Depreciation | 1.87 | 1.78 | 1.66 | 1.57 | 1.47 | 1.37 | 0.22 | 1.66 |
| Interest | 1.02 | 0.94 | 1.03 | 0.86 | 0.86 | 0.91 | 0.82 | 0.64 |
| Profit before tax | 6.85 | 0.07 | 2.62 | 1.84 | 3.13 | 3.38 | 1.31 | 0.94 |
| Tax | 0.00 | 0.00 | (0.13) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Revenue | 42.47 | 43.63 | 47.17 | 64.96 | 85.32 | 97.67 | 185 |
| Revenue growth | -2.7% | -7.5% | -27.4% | -23.9% | -12.6% | -47.3% | - |
| Other income | 0.26 | 1.40 | 31.33 | 1.14 | 1.98 | 46.01 | 1.85 |
| Total expenses | 63.80 | 56.70 | 82.29 | 70.78 | 84.81 | 118 | 162 |
| Employee cost | 10.25 | 9.01 | 7.47 | 6.81 | 6.99 | 10.78 | 14.24 |
| EBITDA | (21.33) | (13.07) | (35.12) | (5.82) | 0.51 | (20.51) | 22.83 |
| EBITDA margin | -50.2% | -30.0% | -74.5% | -9.0% | +0.6% | -21.0% | +12.3% |
| Depreciation | 3.27 | 3.48 | 3.97 | 4.22 | 4.86 | 5.99 | 8.99 |
| Interest | 0.10 | 2.13 | 6.94 | 11.47 | 12.96 | 13.46 | 13.21 |
| Profit before tax | (24.44) | (17.28) | (14.70) | (20.37) | (15.33) | 6.05 | 2.48 |
| Tax | 0.00 | 1.07 | 2.19 | (0.90) | (0.18) | (0.15) | 1.05 |
| Net profit | (2.17) | (19.88) | (44.56) | (19.10) | (14.04) | (29.86) | 1.39 |
| Net profit margin | -5.1% | -45.6% | -94.5% | -29.4% | -16.5% | -30.6% | +0.8% |
| EPS (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.31 | 0.75 |
| Particulars | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 2.37 | 23.66 | 23.66 | 18.66 | 18.66 | 18.66 | 18.66 |
| Reserves & surplus | (6.61) | (4.60) | 14.27 | 20.01 | 39.10 | 53.12 | 50.20 |
| Shareholders' funds (net worth) | 51.12 | 19.06 | 37.93 | 42.67 | 57.76 | 71.78 | 68.86 |
| Minority interest | 0.08 | (0.21) | (0.73) | (0.55) | 0.00 | 0.93 | 0.89 |
| Secured loans | 0.00 | 44.10 | 44.37 | 80.14 | 80.48 | 68.65 | 108 |
| Unsecured loans | 3.02 | 2.13 | 2.17 | 2.24 | 0.00 | 0.00 | 0.00 |
| Total debt | 3.02 | 46.23 | 46.54 | 82.38 | 80.48 | 68.65 | 108 |
| Total liabilities | 54.21 | 65.71 | 96.70 | 137 | 139 | 142 | 179 |
| Assets | |||||||
| Gross block | 74.13 | 72.91 | 79.77 | 79.65 | 79.67 | 77.36 | 90.61 |
| Net block | 35.01 | 37.05 | 44.89 | 48.61 | 52.61 | 54.56 | 69.28 |
| Capital work in progress | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 16.90 | 16.90 | 16.90 | 0.00 |
| Inventories | 11.41 | 9.28 | 10.67 | 16.74 | 16.38 | 16.12 | 27.40 |
| Sundry debtors | 6.03 | 24.83 | 24.28 | 53.78 | 67.96 | 88.69 | 97.51 |
| Cash & bank balances | 8.48 | 2.71 | 2.95 | 2.66 | 2.71 | 2.77 | 2.81 |
| Loans & advances | 10.17 | 11.64 | 10.83 | 4.01 | 35.42 | 19.51 | 28.76 |
| Total current assets | 36.09 | 48.46 | 48.73 | 77.19 | 122 | 127 | 156 |
| Total current liabilities | 17.10 | 47.58 | 36.56 | 38.10 | 49.74 | 54.07 | 50.16 |
| Net working capital | 18.99 | 0.88 | 12.17 | 39.09 | 72.73 | 73.02 | 106 |
| Total assets | 54.21 | 65.71 | 96.70 | 137 | 139 | 142 | 179 |
| Particulars | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.71 | 2.95 | 2.66 | 2.71 | 2.77 | 2.81 | 21.07 |
| Net cash from operating activities | (34.31) | (1.79) | (7.05) | (0.95) | 0.91 | 10.66 | 1.61 |
| Net cash from investing activities | 32.77 | 15.36 | 37.97 | (5.42) | (0.36) | 60.13 | (6.71) |
| Net cash from financing activities | 7.30 | (13.81) | (30.63) | 6.31 | (0.61) | (70.83) | (13.16) |
| Net change in cash | 5.77 | (0.24) | 0.29 | (0.06) | (0.06) | (0.04) | (18.26) |
| Closing cash | 8.48 | 2.71 | 2.95 | 2.66 | 2.71 | 2.77 | 2.81 |
| Particulars | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -2.7% | -7.5% | -27.4% | -23.9% | -12.6% | -47.3% | - |
| EBITDA growth | -63.2% | +62.8% | -503.4% | -1241.2% | +102.5% | -189.8% | - |
| PBT growth | -41.4% | -17.6% | +27.8% | -32.9% | - | +144.0% | -54.9% |
| Net income growth | +89.1% | +55.4% | -133.3% | -36.0% | +53.0% | -2248.2% | - |
| Revenue CAGR (3Y) | -13.2% | -20.0% | -21.5% | -29.5% | -21.4% | - | - |
| EBITDA CAGR (3Y) | +54.2% | - | +19.6% | - | -71.7% | - | - |
| Profitability & leverage | |||||||
| Net income margin | -57.6% | -42.1% | -35.8% | -30.0% | -17.8% | +6.4% | +0.8% |
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | -1.7% | -11.8% | +9.0% |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | -23.4% | -42.4% | +2.1% |
| Debt / equity | 0.70 | 1.63 | 1.60 | 1.62 | 1.15 | 1.26 | 1.53 |
| Long-term debt / equity | 0.34 | 0.41 | 0.05 | 0.37 | 0.36 | 0.25 | 0.35 |
| Interest cover | -0.41 | -12.87 | -17.75 | -114.24 | -297.93 | -50.79 | 95.45 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.58 | 0.57 | 0.59 | 0.82 | 1.10 | 1.17 | 2.10 |
| Inventory turnover | 4.11 | 4.37 | 3.44 | 3.92 | 5.32 | 4.53 | 7.48 |
| Debtors turnover | 2.75 | 1.78 | 1.21 | 1.07 | 1.10 | 1.06 | 1.96 |
| EPS (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.31 | 0.75 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | (17.93) | 8.06 | 16.03 | 20.73 | 30.96 | 38.47 | 36.91 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 47.67 | 26.58 | 42.24 | 38.29 | 35.47 | 34.62 | 39.06 | 33.19 |
| Revenue growth (YoY) | +34.4% | -23.2% | +8.1% | +15.4% | -12.0% | +4.0% | - | - |
| Other income | 1.13 | 1.91 | 1.76 | 1.22 | 1.18 | 0.60 | 1.03 | 0.19 |
| Total expenses | 39.06 | 25.70 | 38.69 | 35.24 | 31.19 | 29.56 | 37.74 | 30.14 |
| EBITDA | 8.61 | 0.88 | 3.55 | 3.05 | 4.28 | 5.06 | 1.32 | 3.05 |
| EBITDA margin | +18.1% | +3.3% | +8.4% | +8.0% | +12.1% | +14.6% | +3.4% | +9.2% |
| Depreciation | 1.87 | 1.78 | 1.66 | 1.57 | 1.47 | 1.37 | 0.22 | 1.66 |
| Interest | 1.02 | 0.94 | 1.03 | 0.86 | 0.86 | 0.91 | 0.82 | 0.64 |
| Profit before tax | 6.85 | 0.07 | 2.62 | 1.84 | 3.13 | 3.38 | 1.31 | 0.94 |
| Tax | 0.00 | 0.00 | (0.13) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 151 | 146 | 152 | 115 | 85.14 | 71.22 | 42.47 |
| Revenue growth | +3.3% | -4.3% | +32.2% | +35.5% | +19.6% | +67.7% | - |
| Other income | 4.76 | 2.74 | 3.52 | 3.27 | 1.70 | 0.75 | 0.26 |
| Total expenses | 135 | 137 | 141 | 99.65 | 75.34 | 60.92 | 64.57 |
| Employee cost | 21.92 | 21.03 | 19.03 | 15.87 | 14.65 | 11.98 | 10.25 |
| EBITDA | 15.94 | 9.03 | 11.11 | 15.70 | 9.80 | 10.30 | (22.10) |
| EBITDA margin | +10.6% | +6.2% | +7.3% | +13.6% | +11.5% | +14.5% | -52.0% |
| Depreciation | 6.07 | 4.89 | 5.00 | 5.33 | 5.49 | 4.48 | 3.27 |
| Interest | 3.66 | 2.73 | 2.29 | 2.04 | 0.79 | 0.74 | 0.10 |
| Profit before tax | 10.97 | 4.15 | 7.34 | 11.60 | 5.22 | 5.83 | (25.21) |
| Tax | (0.13) | 0.00 | 0.00 | 0.28 | 0.00 | 0.00 | 0.00 |
| Net profit | 11.10 | 6.37 | 7.27 | 11.12 | 7.38 | 5.83 | (1.88) |
| Net profit margin | +7.4% | +4.4% | +4.8% | +9.6% | +8.7% | +8.2% | -4.4% |
| EPS (βΉ) | 4.69 | 1.76 | 3.11 | 4.79 | 2.21 | 2.46 | (106.54) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 23.66 | 23.66 | 23.66 | 23.66 | 23.66 | 23.66 | 2.37 |
| Reserves & surplus | 72.49 | 61.15 | 57.18 | 49.80 | 38.31 | 33.11 | (6.78) |
| Shareholders' funds (net worth) | 96.15 | 84.81 | 80.84 | 73.46 | 61.97 | 56.77 | 50.95 |
| Secured loans | 35.63 | 26.70 | 22.89 | 21.42 | 9.04 | 2.50 | 0.00 |
| Unsecured loans | 1.80 | 1.50 | 1.50 | 1.51 | 2.02 | 12.79 | 3.02 |
| Total debt | 37.43 | 28.20 | 24.39 | 22.93 | 11.06 | 15.29 | 3.02 |
| Total liabilities | 138 | 115 | 107 | 97.60 | 73.87 | 72.16 | 53.96 |
| Assets | |||||||
| Gross block | 134 | 106 | 99.49 | 94.66 | 87.94 | 79.57 | 74.09 |
| Net block | 81.79 | 58.78 | 40.21 | 40.23 | 38.85 | 35.97 | 34.97 |
| Capital work in progress | 3.13 | 7.31 | 12.27 | 1.50 | 0.00 | 0.83 | 0.21 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 28.90 | 28.09 | 29.64 | 22.22 | 20.28 | 15.44 | 11.41 |
| Sundry debtors | 43.93 | 40.17 | 45.39 | 41.15 | 14.78 | 9.56 | 6.03 |
| Cash & bank balances | 2.02 | 3.43 | 1.40 | 7.81 | 0.17 | 1.80 | 8.48 |
| Loans & advances | 14.80 | 13.04 | 17.34 | 16.13 | 15.65 | 22.86 | 9.95 |
| Total current assets | 89.65 | 84.73 | 93.77 | 87.31 | 50.88 | 49.66 | 35.87 |
| Total current liabilities | 37.53 | 37.68 | 40.44 | 31.99 | 16.27 | 14.31 | 17.10 |
| Net working capital | 52.12 | 47.05 | 53.33 | 55.32 | 34.61 | 35.35 | 18.77 |
| Total assets | 138 | 115 | 107 | 97.60 | 73.87 | 72.16 | 53.96 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.43 | 1.40 | 7.81 | 0.17 | 1.80 | 8.48 | 2.70 |
| Net cash from operating activities | 15.37 | 22.14 | 9.48 | 4.95 | 9.73 | (13.61) | (34.27) |
| Net cash from investing activities | (22.40) | (21.16) | (15.05) | (7.49) | (6.54) | (5.35) | 32.78 |
| Net cash from financing activities | 5.62 | 1.06 | (0.85) | 10.18 | (4.81) | 12.28 | 7.27 |
| Net change in cash | (1.41) | 2.04 | (6.41) | 7.64 | (1.63) | (6.68) | 5.78 |
| Closing cash | 2.02 | 3.43 | 1.40 | 7.81 | 0.17 | 1.80 | 8.48 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +3.3% | -4.3% | +32.2% | +35.5% | +19.6% | +67.7% | - |
| EBITDA growth | +76.5% | -18.7% | -29.2% | +60.2% | -4.9% | +146.6% | - |
| PBT growth | +164.3% | -43.5% | -36.7% | +122.2% | -10.5% | +9998.0% | -38.3% |
| Net income growth | +74.3% | -12.4% | -34.6% | +50.7% | +26.6% | +410.1% | - |
| Revenue CAGR (3Y) | +9.3% | +19.7% | +28.9% | +39.5% | +25.0% | +14.7% | -13.2% |
| EBITDA CAGR (3Y) | +0.5% | -2.7% | +2.6% | - | - | - | +61.9% |
| Profitability & leverage | |||||||
| Net income margin | +7.4% | +2.9% | +4.8% | +9.8% | +6.1% | +8.2% | -59.4% |
| Return on capital employed | +8.9% | +5.8% | +6.3% | +9.4% | +5.8% | +6.7% | 0.0% |
| Return on net worth | +8.7% | +5.0% | +5.7% | +8.9% | +5.8% | +6.5% | 0.0% |
| Debt / equity | 0.36 | 0.32 | 0.31 | 0.25 | 0.22 | 0.17 | 0.69 |
| Long-term debt / equity | 0.18 | 0.15 | 0.12 | 0.10 | 0.09 | 0.08 | 0.33 |
| Interest cover | 37.08 | 65.94 | 37.48 | 19.67 | 18.33 | 12.71 | -0.39 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.26 | 1.42 | 1.57 | 1.26 | 1.02 | 0.93 | 0.58 |
| Inventory turnover | 5.29 | 5.05 | 5.88 | 5.43 | 4.77 | 5.31 | 4.11 |
| Debtors turnover | 3.58 | 3.41 | 3.52 | 4.12 | 7.00 | 9.14 | 2.75 |
| EPS (βΉ) | 4.69 | 1.76 | 3.11 | 4.79 | 2.21 | 2.46 | (106.54) |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 40.64 | 35.85 | 34.17 | 31.05 | 26.19 | 24.00 | (18.64) |
Similar companies to Bafna Pharma
Bafna Pharma has 3 listed similar companies in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | Company offering a suite of R&D and manufacturing services for small molecules and generics | |||
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. |
Detailed similar companies of Bafna Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bafna Pharma
The website of Bafna Pharma (bafnapharma.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▲ 13.7% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Bafna Pharma (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bafna Pharma
Complete news archive for Bafna Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bafna Pharma
Bafna Pharma was founded in 1981.
Bafna Pharma is headquartered in Chennai, India. It is registered at Chennai, Tamil Nadu, India.
Bafna Pharma has 325 employees.
The primary company behind Bafna Pharma, Bafna Pharmaceuticals Limited, reported revenue of βΉ155 Cr for FY 2026, up 3% year on year.
Bafna Pharma was established in 1981 in Chennai, India, within the pharmaceutical sector. Manufacturing services focused on formulations are offered, with emphasis on exports to regulated and rest-of-world markets. Domestic operations were initiated in 2011 through the acquisition and launch of Raricap, targeting gynaec and paediatric segments. The company operates from its base in India to serve global and local needs.
Bafna Pharma's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Yes, Bafna Pharma is publicly traded on NSE under the ticker symbol BAFNAPH.
Bafna Pharma operates through Bafna Pharmaceuticals Limited.
The legal entities of Bafna Pharma currently have 9 directors, including Palamadai Krishnan Sundaresan, Ravichandran Chitra, Shanmugam Hemalatha and others.
